drugset / Trial / NCT02192723

A Randomized Double-blind Trial With 6 Antipsychotic Drugs for Schizophrenia

NCT02192723

Completed 550 enrolled Beijing HuiLongGuan Hospital
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to compare the efficacy and side effects of 6 commonly used antipsychotic drugs in the treatment of schizophrenia in a Chinese population.

Timeline

Start
2012-06
Primary completion
2014-06
Completion
2014-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Aripiprazole Other / unclassified 10 mg
Subject Aripiprazole Other / unclassified 30 mg
Subject Haloperidol Other / unclassified 6 mg
Subject Haloperidol Other / unclassified 20 mg
Comparator Olanzapine Small molecule 400 mg
Comparator Olanzapine Small molecule 750 mg
Subject Perphenazine Small molecule 16 mg
Subject Perphenazine Small molecule 64 mg
Comparator Quetiapine Small molecule 400 mg
Comparator Quetiapine Small molecule 750 mg
Comparator Risperidone Other / unclassified 2 mg
Comparator Risperidone Other / unclassified 6 mg
Comparator Ziprasidone Small molecule 80 mg
Comparator Ziprasidone Small molecule 160 mg

Indications